Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712564 | 0.96 | EPHX2 (0.46) | EPHX2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4709707 | 0.94 | EPHX2 (0.45) | EPHX2MEN1KMT2AMAPTFAAH | |
| SCHEMBL4712065 | 0.94 | EPHX2 (0.45) | EPHX2MEN1KMT2AMAPTFAAH | |
| SCHEMBL4710004 | 0.94 | EPHX2 (0.45) | EPHX2MEN1KMT2AMAPTFAAH | |
| SCHEMBL4714224 | 0.91 | EPHX2 (0.38) | EPHX2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4711531 | 0.85 | LMNA (0.42) | EPHX2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4714244 | 0.78 | EPHX2 (0.39) | EPHX2ALDH1A1 | |
| SCHEMBL4710035 | 0.77 | ALDH1A1 (0.39) | EPHX2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6452242 | 0.77 | EPHX2 (0.52) | EPHX2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4713498 | 0.74 | EPHX2 (0.41) | EPHX2ALDH1A1MEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1398309-B1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6833388-B2 | 1,3-adamantanedicarboxylic acid-bis(2'-alkyl-2'-adamantyl)-esters; photoresist additive; resin heat resistance improver; pharmaceutical and agrochemical intermediates | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20040157923-A1 | Novel adamantane derivative | IDEMITSU KOSAN CO. LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1398309-A1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157923-A1 | Novel adamantane derivative | TAS1R1, TAS2R1, ADORA1 | EPHX2 2876/4885ALDH1A1 225/4885MEN1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.